Trial reportEuropean journal of clinical pharmacology2009
High absolute bioavailability of methylene blue given as an aqueous oral formulation.
Trial report in European journal of clinical pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 3 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies.Frontiers in pharmacology · 2023Pooled it
- Evaluating the safety of oral methylene blue during swallowing assessment: a systematic review.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2021Pooled it
- Efficacy and safety of methylene blue in the treatment of malaria: a systematic review.BMC medicine · 2018Pooled it
- Pharmacokinetics andAntimicrobial agents and chemotherapy · 2020Trial
- Methylene blue modulates functional connectivity in the human brain.Brain imaging and behavior · 2017Trial
- Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain.Radiology · 2016Trial
- Fifty shades of green and blue: autopsy findings after administration of xenobiotics.Forensic science, medicine, and pathology · 2025Review
- Methylene Blue in Septic Shock: Emerging Evidence, Clinical Applications, and Future Directions.Cureus · 2025Review
- Deciphering Chemical Rules for Drug Penetration into Strongyloides.Pharmaceutics · 2024Article
- Real-time measurements of ATP dynamics via ATeams inAntimicrobial agents and chemotherapy · 2024Article
- In Vitro and Ex Vivo Investigation of the Antibacterial Effects of Methylene Blue against Methicillin-ResistantPharmaceuticals (Basel, Switzerland) · 2024Article
- Methylene Blue-Induced Serotonin Toxicity: Case Files of the Medical Toxicology Fellowship at the New York City Poison Control Center.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2024Article
- A smart hypochlorous acid fluorescent probe enabling Ibuprofen-release for osteoarthritis theranostics.Theranostics · 2024Article
- Article
- Efficacies and ADME properties of redox active methylene blue and phenoxazine analogues for use in new antimalarial triple drug combinations with amino-artemisinins.Frontiers in pharmacology · 2023Article
- A Novel Approach of Combining Methylene Blue Photodynamic Inactivation, Photobiomodulation and Oral Ingested Methylene Blue in COVID-19 Management: A Pilot Clinical Study with 12-Month Follow-Up.Antioxidants (Basel, Switzerland) · 2022Article
- Methylene blue: a controversial diagnostic acid and medication?Toxicology research · 2022Review
- Methylene Blue-Based Combination Therapy with Amodiaquine Prevents Severe Malaria in an Experimental Rodent Model.Pharmaceutics · 2022Article
- Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern.Current research in virological science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMethylene blue (MB) has recently been reevaluated for malaria treatment. With the aim of excluding treatment failures due to low bioavailability, we have investigated the absolute bioavailability of MB given as an aqueous oral formulation and its interaction with chloroquine (CQ).
methodsA phase I study in 16 healthy individuals was performed as a monocenter prospective open randomized intra-individual cross-over comparison of MB single doses [50 mg intravenous (i.v.), 500 mg orally, separated by a 1-week wash-out]. After a second week, the group was split for a randomized parallel group comparison of CQ 750 mg administered orally alone or combined with 500 mg MB orally.
resultsMean MB plasma area under the substrate concentration-time curve (AUC 0-infinity) was 7,639 +/- 3,384 ng/mL*h and 51,171 +/- 17,147 ng/mL*h after i.v. and oral administration, respectively (dosage 1:10), and 76,897 +/- 46,037 ng/mL*h after MB combined with CQ. The absolute bioavailability was 72.3 +/- 23.9%. Co-administration with CQ significantly increased MB plasma concentrations (p <or= 0.016); CQ kinetics remained unaffected.
conclusionThe absolute bioavailability of MB is high. Co-administration of MB and CQ increases plasma, but not whole blood MB concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.